NICM
EWTX icon

Neo Ivy Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Neo Ivy Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,720
Closed -$259K – 329
2024
Q4 		$259K Buy
+9,720
New +$309K 0.05% 215

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Neo Ivy Capital Management's EWTX Position: Q1 2025 in Review

Neo Ivy Capital Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 9,720 shares — an estimated $259K sold.

Neo Ivy Capital Management first reported a position in EWTX in Q4 2024 and held it in 1 quarter. The position peaked at $259K in Q4 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Neo Ivy Capital Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 9,720 Edgewise Therapeutics shares in Q1 2025, an estimated $259K.
  • Neo Ivy Capital Management first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 1 quarter.
  • Neo Ivy Capital Management's Edgewise Therapeutics position peaked at $259K in Q4 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Neo Ivy Capital Management's 13F filing for Q1 2025, filed 6 May 2025.